Abstract
The humanised monoclonal antibody daclizumab is an immunosuppressive agent that reduces acute rejection in renal transplant recipients. It is specific for the a subunit (Tac/CD25) of the interleukin-2 (IL-2) receptor on activated T cells and achieves immunosuppression by competitive antagonism of IL-2-induced T cell proliferation. Daclizumab has advantages over murine antibodies to the IL-2 receptor, including improved effector function, a low potential for immunogenicity and long elimination half-life.
When added to standard cyclosporin-based immunosuppressive therapy with or without azathioprine, daclizumab (1 mg/kg prior to surgery and once every 2 weeks thereafter for a total of 5 doses) significantly reduced the 6-month rate of acute rejection compared with placebo in 2 phase III studies. The mean number of rejection episodes was significantly reduced and the time to first acute rejection significantly increased in daclizumab versus placebo recipients. Patient survival at 1 year after transplantation was significantly higher with daclizumab than placebo in 1 study and showed a trend in favour of the drug in the other study. The 1-year graft survival rate tended to be greater in daclizumab than in placebo recipients in both studies.
In a phase II study, acute rejection rates in patients treated with both daclizumab and mycophenolate mofetil (plus standard cyclosporin-based immunosuppression) were lower than those achieved with mycophenolate mofetil alone.
Preliminary results indicate that daclizumab is also a useful agent in paediatric renal transplant recipients. Further investigation of the efficacy and tolerability of the drug in this patient group is clearly warranted.
Daclizumab does not increase the incidence of adverse events when added to standard cyclosporin-based therapy. The incidence of opportunistic infections, lymphoproliferative disorders and malignancies was not increased above that seen with placebo.
Conclusions: Although the effects of daclizumab on long term graft and patient survival require further investigation, available data indicate that daclizumab is an important advance in renal transplant immunosuppression, reducing acute graft rejection without affecting the tolerability of standard cyclosporin-based immunosuppression.
Pharmacodynamic Properties
Daclizumab is a humanised monoclonal antibody that binds specifically to the a subunit (Tac) of the interleukin-2 (IL-2) receptor present on the surface of activated T lymphocytes. It retains a high affinity for Tac, but has about 3-fold lower affinity than the murine monoclonal antibody from which it was derived.
Saturation of lymphocytes expressing the IL-2 receptor was shown in patients undergoing renal transplantation treated with daclizumab. Receptors remainedsaturated on peripheral blood lymphocytes in daclizumab-treated patients for up to 4 months after transplantation (2 months after the last dose of daclizumab).
Daclizumab antagonises the action of IL-2 at its receptor, thus causing inhibition of IL-2-dependent T lymphocyte proliferation in response to antigen recognition. In vitro studies have shown that daclizumab inhibits human T lymphocyte proliferation to a similar extent to the murine anti-Tac antibody.
Post-transplantation total lymphocyte and lymphocyte subset counts were similar in daclizumab and placebo recipients.
Pharmacokinetic Properties
Available data on the pharmacokinetic properties of daclizumab in renal transplant recipients indicate that a dosage of 1 mg/kg every 14 days for a total of 5 doses can maintain sufficient serum concentrations to provide immunosuppression 3 months after transplantation. Daclizumab has a small volume of distribution (about 5.3L), and systemic clearance is low (estimated at 15.1 ml/h for an 80kg 45-year-old Caucasian male; interindividual variation is about 20% and increases with increasing body weight). The drug has a long terminal elimination half-life (harmonic mean about 480 hours), which is similar to that reported for human immunoglobulin G (IgG).
Clinical Efficacy
Intravenous daclizumab (1 mg/kg within 24 hours before surgery and once every 2 weeks thereafter for a total of 5 doses) reduces the incidence of acute biopsyproven rejection in cadaver kidney transplant recipients.
The acute rejection rate at 6 months (the primary efficacy end-point) was significantly lower in patients treated with daclizumab plus cyclosporin-based double or triple therapy than in those treated with placebo plus cyclosporin-based therapy in 2 large phase III multicentre studies (rejection rates of 22 and 28% with daclizumab versus 35 and 47% with placebo). In addition, the mean number of rejection episodes was significantly lower and the time to acute rejection significantly longer with daclizumab.
The graft survival rate after 1 year was higher in daclizumab recipients in both studies (88 and 95% vs 83 and 90%, respectively), but the difference did not reach statistical significance.
Patient survival after 1 year was significantly higher in daclizumab compared with placebo recipients in 1 study (99 vs 94%), but not in the other (98 vs 96%).
The requirement for additional antilymphocyte therapy to treat rejection was lower with daclizumab than placebo, as was the cumulative dose of corticosteroids; however, only 1 of the phase III studies found these differences to be statistically significant.
In a phase II study, the graft rejection rate at 6 months after transplantation with combined daclizumab plus mycophenolate mofetil and standard immunosuppressive therapy (12%) was lower than that observed historically with standard immunosuppression plus mycophenolate mofetil.
Daclizumab showed promising results in a preliminary study in paediatric renal transplant recipients (median age 10 years). At follow-up (44% followed for ≥1 year and 87% for ≥6 months), only 3 of 54 patients (5%) treated with daclizumab [1mg/kg prior to transplantation and once every 2 weeks thereafter for a total of 5 doses, in addition to standard immunosuppressive therapy (predominantly cyclosporin-based)] experienced an acute rejection episode.
Tolerability
Available data from phase III studies indicate that daclizumab is well tolerated in the majority of patients. The incidence of all adverse events considered to be possibly or probably related to treatment was similar in daclizumab and placebo recipients, as was the incidence of severe events. Gastrointestinal disturbance was the most common event in both treatment groups, but was not considered to be treatment related. Daclizumab did not increase the incidence of opportunistic infections [bacterial, fungal or viral (including cytomegalovirus)] compared with placebo, and lymphoproliferative disorders and malignancies were rare. Specific toxicities related to the infusion of daclizumab such as allergic or anaphylactic reactions were not observed. First-dose adverse events occurred in a similar proportion of daclizumab and placebo recipients.
Daclizumab has a low potential for immunogenicity. Anti-daclizumab antibodies were found in about 10 to 15% of patients treated with the drug; however, their presence did not appear to alter the pharmacological properties or clinical efficacy of daclizumab.
Dosage and Administration
The recommended dosage of daclizumab for immunosuppression in renal transplant recipients is 1 mg/kg administered within 24 hours before surgery and once every 2 weeks thereafter for a total of 5 doses. Daclizumab 1 mg/kg should be diluted in 50ml of sterile 0.9% saline and administered intravenously via a peripheral or central vein over a 15-minute period.
No drug interactions have been observed after administration of daclizumab with standard immunosuppressive regimens.
Similar content being viewed by others
References
Brown Jr PS, Parenteau GL, Dirbas FM, et al. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival. Proc Natl Acad Sci U S A 1991 Apr 1; 88: 2663–7
Tinubu SA, Hakimi J, Kondas JA, et al. Humanized antibody directed to the IL-2 receptor beta-chain prolongs primate cardiac allograft survival. J Immunol 1994 Nov 1; 153: 4330–8
Guex-Crosier Y, Raber J, Chan C-C, et al. Humanized antibodies against the α-chain of the IL-2 receptor and against the β-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J Immunol 1997; 158: 452–8
Hart BA, Hakimi J. Evaluation of the effect of humanized anti-Tac (HAT) and humanized Mikβ1 on collagen-induced arthritis in the rhesus monkey. New Jersey: Hoffman-La Roche (New Jersey), 1996. Report no.: N-138779. (Data on file)
Anasetti C, Lin A, Nademanee A, et al. Aphase II/III randomized, double-blind, placebo-controlled multicenter trial of humanized anti-Tac for prevention of acute graft-versus-host disease (GVHD) in recipients of marrow transplants from unrelated donors [abstract]. Blood 1995 Nov 15; 86 Suppl. 1: 621
Queen C, Schneider WP, Selick HE, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A 1989; 86: 10029–33
Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161–5
Junghans RP, Waldmann TA, Landolfi NF, et al. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res 1990 Mar 1; 50: 1495–502
Vincenti F, Lantz M, Birnbaum J, et al. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation 1997; 63: 33–8
Data on file. Nutley, New Jersey: Hoffman La Roche Inc. 1999
Savo AM, Book BK, Henson S, et al. Daclizumab rapidly saturates interleukin-2 receptor-alpha (CD25) on lymph node lymphocytes in children. Transplant Proc 1999; 31: 1182–3
Hakimi J, Ha VC, Lin P, et al. Humanized Mikβ1, a humanized antibody to the IL-2 receptor β-chain that acts synergistically with humanized anti-TAC. J Immunol 1993 Jul 15; 151: 1075–85
Fayer BE, Soni PP, Binger MH, et al. Determination of humanized anti-Tac in human serum by a sandwich enzyme linked immunosorbent assay. J Immunol Methods 1995 Oct 12; 186: 47–54
Summary of product characteristics for Zenapax (dacliximab). New Jersey, USA: Hoffman-La Roche (New Jersey), 1997. Report no. RO 24-7375. (Data on file)
Nashan B, Light S, Hardie IR, et al. Reduction of acute renal allograft rejection by daclizumab. Transplantation 1999; 67: 110–5
Ekberg H, Backman L, Tufveson G, et al. Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. Transplant Proc 1999; 31: 267–8
Kirkman RL, Vincenti F, Pescovitz MD, et al. A phase I/II randomized double-blind placebo-controlled study of Zenapax in combination with Cellcept, Neoral and steroids. Nutley, USA: Hoffman La Roche Inc. (Nutley), 1998. (Data on file)
Vincenti F, Grinyo J, Ramos E, et al. Can antibody prophylaxis allow sparing of other immunosuppressives? Transplant Proc 1999; 31: 1246–8
Nevins T, Ettenger R, Potter D, et al. Daclizumab (Zenapax) in pediatric (PED) renal allografts: final data [abstract no. 469]. Transplantation 1999; 67: S124
Zenapax product monograph. Basel, Switzerland: F Hoffman-La Roche (Basel), 1997.
Hengster P, Pescovitz MD, Hyatt D, et al. Cytomegalovirus infections after treatment with daclizumab, an anti-IL-2 receptor antibody for prevention of renal allograft rejection. Transplantation 1999; 68: 310–3
Stiller CR, Opelz G. Should cyclosporine be continued indefinitely? Transplant Proc 1991; 23(1): 36–40
Simmons WD, Rayhill SC, Sollinger HW. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Drug Saf 1997; 17: 75–92
Bardsley-Elliot A, Noble S, Foster RH. Mycophenolate mofetil. A review of its use in the management of solid organ transplantation. BioDrugs 1999; 12(5): 363–410
Waldmann TA. The interleukin-2 receptor. J Biol Chem 1991; 266: 2681–4
Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function and clinical application. Ann Intern Med 1990; 113:619–27
Soulilloul J-P, Cantarovich D, Le Mauff B, et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection for renal allografts. N Engl J Med 1990; 322: 1175–82
Kirkman RL, Shapiro ME, Carpenter CB, et al. A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation. Transplantation 1991; 51: 107–13
Kirkman RL, Barrett LV, Gaulton GN, et al. Administration of an anti-interleukin-2 receptor monoclonal antibody prolongs cardiac allograft survival in mice. J Exp Med 1985; 162: 358
Kirkman RL, Barrett LV, Koltun WA, et al. Prolongation of murine cardiac allograft survival by the anti-interleukin-2 receptor monoclonal antibody AMT-13. Transplant Proc 1987; 19:618
Kupiec-Weglinski JW, Diamantstein T, Tilney NL, et al. Therapy with a monoclonal antibody to the interleukin-2 receptor spares T suppressor cells and prevents/reverses acute allograft rejection. Proc Natl Acad Sci U S A 1986; 83: 2624
Kupiec-Weglinski JW, Hahn HJ, Kirkman RL, et al. Cyclosporin potentiates the imunosuppressive effects of anti-interleukin-2 receptor monoclonal antibody therapy. Transplant Proc 1988; 20: 2076–16
Reed MH, Shapiro ME, Strom TB, et al. Prolongation of primate renal allograft survival by anti-Tac, an anti-human IL-2 receptor monoclonal antibody. Transplantation 1989; 47: 55
Onrust SV, Wiseman LR. Basiliximab: new drug profile. Drugs 1999; 57(2): 207–13
Nashan B, Moore R, Amlot P, et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1195–8
Lewis DA, Guzzetta AW, Hancock WS, et al. Characterization of humanized anti-TAC, an antibody directed against the interleukin 2 receptor, using electrospray ionization mass spectrometry by direct infusion, LC/MS, and MS/MS [in English]. Anal Chem 1994 Mar 1; 66: 585–95
Kaufman DB, Stuart J, Leventhal JR, et al. Steroid avoidance in kidney transplantation. 25th Annual Meeting of the American Society of Transplant Surgeons (ASTS); 1999 May 19–21; Chicago, S619
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wiseman, L.R., Faulds, D. Daclizumab. Drugs 58, 1029–1042 (1999). https://doi.org/10.2165/00003495-199958060-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199958060-00006